子宫内膜癌患者血清has-miR-141的表达及其临床意义

目的：探讨人类微小RNA-141（has-miR-141）在子宫内膜癌患者血清中的表达及其临床意义。方法收集55例子宫内膜癌患者术前24 h内的血清标本，以同期收治的12例子宫肌瘤患者术前24 h内的血清和5例健康志愿者的血清作为对照组，应用实时荧光定量PCR技术检测子宫内膜癌患者和对照组血清中has-miR-141的表达水平，并分析has-miR-141表达水平与55例子宫内膜癌患者的临床病理危险因素的关系。结果子宫内膜癌患者的血清has-miR-141的表达水平（2.6295±2.038）高于对照组的（1.561±0.695），差异有统计学意义（P﹤0.05）。子宫内膜癌患者血清中has-miR-141表达与组织病理分型、淋巴结转移和临床分期诊断有关（P﹤0.05），非子宫内膜样癌、淋巴结转移、Ⅲ期+Ⅳ期患者has-miR-141的表达水平高于子宫内膜样癌、无淋巴结转移、Ⅰ期+Ⅱ期患者。不同组织病理分级、年龄、CA125值患者血清中has-miR-141的表达水平比较，差异无统计学意义（P﹥0.05）。结论子宫内膜癌患者血清中has-miR-141呈高表达水平，且与淋巴结转移、病理分型及临床分期有关。has-miR-141有可能成为一种诊断子宫内膜癌的新型标志物，同时有可能作为进展期子宫内膜癌的诊断依据，从而为子宫内膜癌的诊断及治疗提供有效帮助。

Expression of has-miR-141 in serum of patients with endometrial cancer and the clinical significance

Objective To investigate the expression of the has-miR-141 in the serum of patients with endometrial can-cer and the clinical significance. Method 55 blood samples from patients with endometrial cancer, and in the same peri-od 12 serum samples from patients with hysteromyoma were collected within 24 h before surgery, while another 5 blood samples were collected from healthy volunteers as control, then real-time quantitative PCR was used to detect the expres-sion of has-miR-141 in those specimens, and the correlation between clinical pathological risk factors and the expression of has-miR-141 in 55 cases of endometrial cancer was analyzed. Result The expression of has-miR-141 in endometrial cancer patients (2.6295±2.038) was significant higher than that in control group (1.561±0.695) (P<0.05). The expression of has-miR-141 was closely related with pathological types, lymph node metastasis and clinical staging (P<0.05). The ex-pressions in patients with non-endometrioid adenocarcinoma, lymph node metastasis and at stage III-IV were higher than those with endometrioid adenocarcinoma, without lymph node metastasis and at stage I-II. The expressions were of no sta-tistically significant difference (P>0.05) in patients with different histopathological stages, age and CA125 levels. Conclu-sion The has-miR-141 is highly expressed in the serum of patients with endometrial cancer, and is closely related with lymph node metastasis, pathological types and clinical staging, making it a promising alternative predictor in diagnosis of endometrial cancer, furthermore it may play a role in determining the progression of advanced endometrial cancer, provid-ing evidence for the early diagnosis and treatment of endometrial cancer.